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PLA2 (phospholipase A2) group III is an atypical sPLA2 (secre-
tory PLA2) that is homologous with bee venom PLA2 rather
than with other mammalian sPLA2s. In the present paper, we
show that endogenous group III sPLA2 (PLA2G3) is expressed in
mouse skin and that Tg (transgenic) mice overexpressing human
PLA2G3 spontaneously develop skin inﬂammation. Pla2g3-Tg
mice over 9 months of age frequently developed dermatitis
with hyperkeratosis, acanthosis, parakeratosis, erosion, ulcer and
sebaceousglandhyperplasia.Thedermatitiswasaccompaniedby
inﬁltration ofneutrophilsandmacrophagesandbyelevatedlevels
ofpro-inﬂammatorycytokines,chemokinesandprostaglandinE2.
In addition, Pla2g3-Tg mice had increased lymph aggregates
and mucus in the airway, lymphocytic sialadenitis, hepatic ex-
tramedullary haemopoiesis, splenomegaly with increased popu-
lations of granulocytes and monocytes/macrophages, and
increasedserumIgG1.Collectively,theseobservationsprovidethe
ﬁrst demonstration of spontaneous development of inﬂammation
in mice with Tg overexpression of mammalian sPLA2.
Key words: dermatitis, phospholipase A2, phospholipid,
prostaglandin, splenomegaly, transgenic mouse.
INTRODUCTION
PLA2 (phospholipase A2) enzymes catalyse the hydrolysis of the
sn-2 position of glycerophospholipids to give rise to fatty acids
and lysophospholipids. They are subdivided into several groups:
high-molecular-mass intracellular PLA2s with a catalytic serine
residue, including cPLA2 (cytosolic PLA2)a n di P L A 2 (Ca
2+-
independent PLA2) enzymes, and low-molecular-mass disulﬁde-
rich Ca
2+-dependent sPLA2 (secretory PLA2) family with a
catalytic histidine residue. To date, ten catalytically active sPLA2
enzymes have been identiﬁed in mammals (IB, IIA, IIC, IID,
IIE, IIF, III, V, X and XIIA). On a structural basis, these
enzymes are subdivided further into three branches, namely
group I/II/V/X, group III and group XII [1–3]. Individual sPLA2s
exhibit unique tissue and cellular localizations and enzymatic
properties,suggestingtheirdistincttissue-speciﬁcrolesinvarious
pathophysiological events.
Because group IIA sPLA2 (PLA2G2A; or synovial sPLA2)
is strongly induced during inﬂammatory conditions such as
rheumatoid arthritis or sepsis and because sPLA2s from snake
or bee venom can elicit inﬂammation when administered in vivo,
it has long been thought that sPLA2 contributes to inﬂammation,
probably by augmenting the generation of pro-inﬂammatory lipid
mediators [1–3]. However, Tg (transgenic) mice overexpressing
PLA2G2A do not show any sign of inﬂammation, even though
they have alopecic skin [4], raising the question as to whether
this sPLA2 actually exerts a pro-inﬂammatory role in vivo.
Although recent gene targeting studies of new members of the
sPLA2 family, group V (PLA2G5) and group X (PLA2G10),
have provided several lines of evidence that they participate in
some types of inﬂammation [5–8], general understanding of the
roles played by sPLA2s in the onset of inﬂammation, including
their modes of action, is still incomplete and needs further
clariﬁcation. Nonetheless, Tg strategies are still likely to provide
some functional and mechanistic insights into the in vivo actions
of sPLA2s, as knowledge of the antibacterial and pro-atherogenic
propertiesofsPLA2shasbeenadvancedbystudiesusingPla2g2a-
Tg mice [9,10]. However, the early mortality of Pla2g5-Tg mice
[11] and macrophage-speciﬁc Pla2g10-Tg mice [12] due to lung
injury probably resulting from aberrant surfactant degradation
limits their subsequent use. So far, there has been no sPLA2-Tg
mousemodelthatspontaneouslydevelopssystemicinﬂammation.
Group III sPLA2 (PLA2G3) is unique in that it consists of a
central sPLA2 (S) domain, which is homologous with bee venom
sPLA2 rather than with other mammalian sPLA2s, ﬂanked by
distinctive N- and C-terminal domains [13]. Forced expression of
PLA2G3 or its central S domain alone in several cell types results
in increased arachidonic acid metabolism, for which its potency
is superior to that of PLA2G2A and next to that of PLA2G10
and PLA2G5 [14,15]. In an effort to elucidate the functions of
PLA2G3 in vivo, we have recently generated Tg mice expressing
human PLA2G3 in all tissues under the control of the CAG
(chicken β-actin) promoter. An initial study of Pla2g3-Tg mice
provided the novel information that PLA2G3 can hydrolyse
PC (phosphatidylcholine) in plasma lipoproteins to facilitate
macrophage foam cell formation ex vivo and atherosclerosis
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in vivo [16]. In the present study, we have demonstrated another
aspect of Pla2g3-Tg mice in that they spontaneously develop
inﬂammation in multiple organs as they age. This mouse model
will therefore be useful for analysing and understanding the
molecular events in inﬂammation caused by increased expression
of sPLA2.
MATERIALS AND METHODS
Animals
All mice were housed in climate-controlled (21◦C) speciﬁc
pathogen-free facilities with a 12 h light/12 h dark cycle, with
free access to standard laboratory food (Picolab mouse diet 20;
Laboratory Diet) and water. All procedures involving animals
were performed in accordance with protocols approved by
the Institutional Animal Care and Use Committee of Showa
University, in accordance with the Standards Relating to the Care
and Management of Experimental Animals in Japan. The
generation of Pla2g3-Tg mice has been reported previously [16].
RT (reverse transcription)–PCR
Total RNA was extracted from mouse tissues with TRIzol®
reagent (Invitrogen). For RT–PCR, ﬁrst-strand cDNA synthesis
was carried out using SuperScript III reverse transcriptase kit
(Invitrogen). Total RNA (5 μg) was used in reactions primed
with oligo(dT) (12–18-mer) primer (Invitrogen) to obtain cDNA.
Then, 1 μl of the synthesized cDNA was used as the template for
the mRNA-ampliﬁcation reactions. The PCR ampliﬁcation was
performed on a GeneAmp9600 PCR system (PerkinElmer) with
an ExTaq kit (TaKaRa Bio). The primers used are as follows:
5
 -GAAAGCATGATCCGCGACGTGGAA-3
  and 5
 -CCCTTC-
TCCAGCTGGAAGACTCCT-3
  for mouse TNFα (tumour
necrosis factor α); 5
 -AGGGCTGCTTCCAAACCTTTGACC-3
 
and 5
 -CCAGTTGGGGAACTCTGCAGACTC-3
  for mouse IL
(interleukin)-1β;5
 -CAGAGGATACCACTCCCAACAGAC-3
 
and 5
 -CCTTAGCCACTCCTTCTGTGACTC-3
  for mouse IL-6;
5
 -CAGCTAGTTGTCATCCTGCTCTTC-3
  and 5
 -GGTGCAG-
CTTATCGATGAATCCAG-3
  for mouse IL-4; 5
 -GCTACACA-
CTGCATCTTGGCTTTG-3
  and 5
 -GTGGGTTGTTGACCTC-
AAACTTGG-3
  for mouse IFNγ (interferon γ); 5
 -CGTGCA-
CTGAGGCTCACAAATGTTTC-3
  and 5
 -TTTCTTGCACCA-
GCCATGAGC-3
  for mouse IL-12 p40 subunit; 5
 -CATGCTT-
CTGGGCCTGCTGTTC-3
  and 5
 -CAGAAGTGCTTGAGGTG-
GTTGTGG-3
  for mouse CCL2/MCP-1 (monocyte chemoat-
tractant protein-1); 5
 -AAGGGGCCCAAGATCCGCTACA-3
 
and 5
 -GTAGACCCTGCGCTTCTCGTTCCA-3
  for mouse
CXCL14/BRAK (breast- and kidney-expressed chemokine);
5
 -GAGCACTGGCCACTCTTCAGAGTCAG-3
  and 5
 -CGAG-
GAGTTCCCAGCAGAATCTCCAA-3
  for human PLA2G3; 5
 -
GGCTGAGGCCACCTCATATACTTC-3
  and 5
 -TCCTTTGC-
CCTCAGCACAGTCAAG-3
  for mouse PLA2G3; 5
 -GGTCT-
CCTCACACTGGCTTGGTTC-3
  and 5
 -CAGTAGACCAGC-
TTCCGGTCACAG-3
  for mouse PLA2G5; 5
 -GACCCGGA-
TTCAGCGAAGCAACCA-3
  and 5
 -CAGCTCCTCGTCACA-
CCTGCACAA-3
  for mouse PLA2G10; 5
 -GCTGGCCGGT-
ATAACTGCAA-3
  and 5
 -ACACAGTTGCCTTTCACACCA-
3
  for mouse PLA2G2D; 5
 -ACCTCCCATTGCCCTGGCTT-
3
  and 5
 - GGCCCAGTACACAGCTTGTTGG-3
  for mouse
PLA2G2E;5
 -GGTTAAACACTCCACTGGACGGAA-3
  and5
 -
CTCGGTACTTGTTCCTGTATGGGT-3
  for mouse PLA2G2F;
5
 -CGCTCCATTAAGCTGTGGTTTGTGATTCGG-3
  and 5
 -
AGACTGGCTCCTGGCTGCTTGATGATCTTC-3
  for mouse
HDC (histidine decarboxylase); 5
 -ACCACATTCTCGCCC-
TTACAT-3
  and 5
 -TCTCAGTTTCACCTCCCTCAG-3
  for
mMCP (mouse mast cell protease)-4; 5
 -ATAACAGTCCTC-
CTAGGAGCC-3
  and 5
 -GATCCAGGGCCTGTAATGGGA-3
 
for mMCP-5; 5
 -GCACATCAAAAGCCCACAGC-3
  and 5
 -TA-
GACAGGGGAGACAGAGGAC-3
  for mMCP-6; and 5
 -TCG-
TGGATCTGACGTGCCGCCTG-3
  and 5
 -CACCACCCTGTT-
GCTGTAGCCGTAT-3
  for mouse GAPDH (glyceraldehyde-
3-phosphate dehydrogenase). The PCR products were analysed
on a 1.5% agarose gel and visualized using ethidium bromide
staining.
Quantitative RT–PCR
For quantitative RT–PCR, cDNA synthesis was performed
using the high-capacity cDNA reverse transcription kit (Applied
Biosystems). The reaction was carried out on an ABI Prism
7000 sequence detection system (Applied Biosystems) with
TaqMan gene expression master mix (Applied Biosystems).
Pre-designed TaqMan assays (Applied Biosystems) were used
to determine gene expression: Mm00839636 for mouse CD68,
Mm00478374 and Mm00478374 for mouse COX (cyclo-
oxygenase)-1 and -2 respectively, Mm00447040 for mouse
cPLA2α,andMm00452105andMm00460181formousemPGES
(microsomal prostaglandin E synthase)-1 and -2 respectively.
Histochemistry
Formalin-ﬁxed tissues were embedded in parafﬁn, sectioned,
mounted on glass slides, deparafﬁnized in xylene and rehydrated
in ethanol with increasing concentrations of water. The cell
type was identiﬁed from conventional haematoxylin and eosin
staining. For PAS (periodic acid–Schiff) staining, tissue sections
weredeparafﬁnized,rehydratedandplacedin0.5%periodicacid
solution for 5 min. After washing in water, the sections were
placed in Coleman’s Schiff reagent for 15 min, washed in water
for 10 min and counterstained with haematoxylin solution for
15 min. After washing in water for 15 min, the sections were
dehydrated and mounted with resinous medium.
Measurement of eicosanoids
The contents of PGE2 (prostaglandin E2)a n dL T B 4 (leukotriene
B4) in mouse skins were quantiﬁed using PGE2 and LTB4 enzyme
immunoassay kits (Cayman Chemicals).
Measurement of MPO (myeloperoxidase) activity
The tissue samples were homogenized in 50 mM potassium
phosphate buffer (pH 6.0) containing 1% (w/v) hexadecyl-
trimethylammonium bromide and centrifuged at 12000 g for
15 min at 4◦C. An aliquot (30 μl) was added to 180 μlo f
the buffer containing 0.167 mg/ml o-dianisidine dihydrochloride
and 0.0005% (v/v) hydrogen peroxidase (Sigma–Aldrich). After
appropriate periods of incubation at 37◦C, the absorbance at
460 nm was measured. MPO activity was calculated using a
standard curve generated with human MPO (Sigma), and values
were normalized to protein concentration.
Determination of cell types in blood circulation
Blood was collected from mouse tail biopsy with 10 mM EDTA
as an anticoagulant. The blood samples were applied to a clinical
blood cell analyser VetScan HM (Abaxis) to determine the
numbers of lymphocytes, granulocytes, monocytes, erythrocytes
and platelets, the haemoglobin content and the haematocrit value.
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Flow cytometry (FACS)
Suspensions of 10
6 splenic cells were treated on ice with anti-
[mouse CD16/CD32 (FcγRII/RIII)] monoclonal antibody (BD
Biosciences) to block cell-surface Fcγ receptors. Then the cells
were incubated with FITC-, phycoerythrin- or Alexa Fluor® 488-
labelled monoclonal antibodies against mouse CD3, CD4, CD8,
CD11b (Mac1), CD11c, CD21, CD23, CD45R, Gr-1, NK1.1,
sIgD and sIgM (BD Biosciences). Flow cytometric analysis was
carried out on a FACS Aria cell-sorting system (BD Biosciences).
ESI (electrospray ionization)–MS
Lungs of mice were lavaged with 1 ml of SET buffer (250 mM
sucrose, 0.5 mM EDTA and 20 mM Tris/HCl, pH 7.4), and
the resulting bronchoalveolar lavage ﬂuid was used after
centrifugation at 160 g for 10 min at 4◦C to remove the cells
and tissue debris. Lipids were extracted from the bronchoalveolar
lavage ﬂuid using the method of Bligh and Dyer [16a]. PC
with C14:1–C14:1 (diacyl) was added to the samples (1 nmol of
internal standard per 1 mg of protein equivalents) as an internal
standard. MS spectra were obtained on a Quattro Micro tandem
quadrupolemassspectrometer(Micromass)equippedwithESI,as
describedpreviously[11].Lipidextractswerereconstitutedin2:1
chloroform/methanol (100–300 μmol of phosphorus/l), and 2 μl
of the sample was injected per run. The samples were introduced
by means of a ﬂow injector into the ESI chamber at a ﬂow rate
of 4 μl/min in a solvent system of acetonitrile/methanol/water
(2:3:1, by vol.) containing 0.1% (v/v) ammonium formate
(pH 6.4). The mass spectrometer was operated in the positive-
and negative-scan modes. The ﬂow rate of the nitrogen drying
gas was 12 l/min at 80◦C. The capillary and cone voltages were
set at 3.7 kV and 30 V respectively, argon at (3–4)×10
4 Torr
(1Torr=133.3 Pa) was used as the collision gas, and a collision
energy of 30–40 V was used for obtaining fragment ions for
precursor ions.
Determination of serum immunogloblin levels
Serum titres of IgM, IgG1,I g G 2 and IgE were determined using a
mouse IgX ELISA quantiﬁcation kit (Bethyl Laboratories).
RESULTS
Pla2g3-Tg mice develop dermatitis
Pla2g3-Tgmiceappearednormalatbirthandshowednoapparent
abnormality up to 9 months of age under our housing conditions
(except that the Tg mice had altered plasma lipoproteins,
as described in [16]). Subsequently, however, we noted that
about one-third of PLA2G3 mice, both male and female,
experienced gradual hair loss on their facial, neck and dorsal
skin,whichsubsequently(typicallywithin2–3months)developed
into focally alopecic lesions that were often ﬁlled with
pus (Figure 1A). Behaviour suggestive of increasing itching
eventuallyworsenedthelesionsfurther.Neitherage-matchednon-
Tg WT (wild-type) mice nor Tg mice expressing LNL (LoxP–
neomycin-resistancegene–LoxP)–PLA2G3(i.e.miceharbouring
the PLA2G3 transgene in a silent state [16]) exhibited these skin
abnormalities (Figure 1A), implying that the phenotype resulted
from Tg overexpression of PLA2G3. Subsequent studies mostly
focused on aged (9–12 months) PLA2G3 mice that developed
dermatitis, with age-matched WT mice as controls.
Histological examination revealed many abnormalities in the
skin of Pla2g3-Tg mice (Figure 1B, panels b–i) as compared
with the normal appearance of the skin of WT mice (Figure 1B,
panel a). Pla2g3-Tg mice (1-year-old) showed dense cellularity
in the dermis with markedly increased numbers of haematoxylin-
stained nuclei, which were mostly ascribed to inﬁltrating
polymorphonuclear neutrophils and macrophages (Figure 1B,
panelsb–i).Pla2g3-Tgmicehadthickenedepidermis(acanthosis)
with dense corniﬁed layers, sebaceous gland hyperplasia and
epidermal rete peg formation (downward papillary projection
of the epidermis) (Figure 1B, panels b and c). In contrast
with hair shafts that emerged straight out of the hair canals in
WT mice (Figure 1B, panel a), those in Pla2g3-Tg mice often
bent over within the canals, probably because highly thickened
interfollicular and follicular keratinocyte layers prevented the
protrusion of the hair shafts (Figure 1B, panel b). Parakeratosis,
which represents unusual retention of nuclei in the outermost
corniﬁed layers, was frequently observed in severe lesions in
Pla2g3-Tg mice (Figure 1B, panels c–e), where the epidermis
was focally lost resulting in cutaneous erosion and ulcers with
massive neutrophil inﬁltration (Figure 1B, panels d, e, g and h).
RT–PCR showed that pro-inﬂammatory cytokines, including
TNFα,I L - 1 β and IL-6, and CCL2/MCP-1 were highly expressed
in the inﬂamed skin lesions of Pla2g3-Tg mice, but not in
control mice (Figure 2A). CXCL14 (BRAK), a skin chemokine,
was faintly detected in WT skin and was also increased in
Tg skin. The TH2 cytokine IL-4 was weakly, but signiﬁcantly,
detected in Tg, but not WT, skin, whereas the TH1 cytokines
IFNγ and IL-12 were below the detection limit in both genotypes
(Figure 2A). Moreover, MPO activity, which mirrors neutrophil
inﬁltration, in skin sections was markedly elevated in Pla2g3-Tg
micecomparedwithWTmice(Figure2B).QuantitativeRT–PCR
demonstrated a marked increase in CD68, a macrophage marker,
inPla2g3-TgskinrelativetoWTskin(Figure2C),consistentwith
macrophage inﬁltration. In contrast, the expression levels of mast
cell markers, including mMCP-4, -5 and -6 (mast cell proteases),
were unchanged between control and PLA2G3 skin (Figure 2D),
indicating that the mast cell population was unaffected by Tg
expression of PLA2G3. Therefore increased expression of HDC
(a histamine-biosynthetic enzyme) in the Tg skin (Figure 2D)
might reﬂect the increase in macrophages, in which a trace level
ofHDCisexpressed[17],or,alternatively,theexpressionofHDC,
but not mMCPs, in mast cells might be speciﬁcally controlled by
PLA2G3.
Furthermore, a marked increase in PGE2 was observed in
the skin of Pla2g3-Tg mice compared with that of WT mice
(Figure 3A). Consistent with this, expression of COX-2 and
mPGES-1, which are inducible enzymes that act sequentially in
the PGE2-biosynthetic pathway downstream of PLA2 [18], was
higher in Pla2g3-Tg skin lesions than in WT skin (Figure 3B).
In particular, the induction of COX-2 was markedly higher in Tg
skin relative to WT skin, whereas cutaneous expression levels
of cPLA2α, COX-1 and mPGES-2 were similar between
the genotypes (Figure 3B). Therefore increased expression
of pro-inﬂammatory cytokines by inﬁltrating macrophages or
hyperplasic epidermal keratinocytes may contribute to the
induction of COX-2 and mPGES-1, which in turn leads to
increased PGE2 synthesis in Pla2g3-Tg skin. Although we also
measured LTB4, a leukotriene produced by neutrophils and
macrophages, in skin homogenates as well as serum of Pla2g3-
Tg mice, it was below the detection limit probably because of its
instability.
The expression of various sPLA2 enzymes in the skin of WT
and Tg mice is shown in Figure 3(C). Interestingly, transcripts
of endogenous mouse PLA2G3 were clearly detected in control
skin(Figure3C).Toourknowledge,thisistheﬁrstdemonstration
that PLA2G3 is intrinsically expressed in mouse skin. Expression
of PLA2G2D and PLA2G5 was increased in Tg lesion skin
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Figure 1 Histology of dermatitis in aged Pla2g3-Tg mice
(A) Appearance of 1-year-old WT (panel a), LNL–Pla2g3-Tg (LNL-III-Tg) (panel b) and CAG–Pla2g3-Tg (III-Tg) (panels c and d) mice. Whereas WT and LNL–Pla2g3-Tg mice were grossly normal,
CAG–Pla2g3-Tg mice frequently developed lesion areas on facial, neck and back skins (red arrows). (B) Skin histology of WT and Pla2g3-Tg mice. In contrast with the normal appearance of the
skins of WT mice (panel a), those of Pla2g3-Tg mice showed multiple abnormalities (panels b–i) that are similar to those seen in psoriasis and atopic dermatitis in humans. Typically, the Tg skins
exhibit hyperkeratosis(darkarrows; panels b, c and g) with thickened corniﬁed layers (bluearrows; panelsc and g), acanthosis (yellow arrows;panel c) and parakeratosis(open green arrows;panels
c–e). Sebaceous glands (green arrows) are hyperplasic and hair shafts (broken arrows) were bent over within hair follicles in Pla2g3-Tg mice (panel b) compared with normal appearance of those
in control mice (panel a). Epidermis was focally lost, where erosion and ulcer (stars) were found in the Tg mice (panels d, e, g and h). Boxed areas in panels d and g are magniﬁed in panels e and
h respectively. A lot of inﬂammatory cell inﬁltrates were found in the dermis of the Tg mice (green asterisks, panels c–h). A magniﬁed vision of the Tg dermis demonstrates the accumulation of
polymorph nuclear neutrophils and ﬂat-shaped mononuclear macrophages, as exempliﬁed by light blue arrows and red arrows respectively in panel i.
compared with unaffected Tg skin and with WT skin, whereas
expression of PLA2G10 was below the detection limit in the
skin of both genotypes (Figure 3C). Another intriguing ﬁnding is
constitutive expression of PLA2G2E and PLA2G2F at relatively
high levels in the skin of both genotypes (Figure 3C).
Inﬂammation in other tissues
The ﬁnding that several inﬂammatory markers were elevated
in the skin lesions of Pla2g3-Tg mice (Figures 2 and 3) prompted
us to examine whether other tissues in these mice also display
inﬂammatory symptoms. We showed previously that Pla2g5-Tg
mice die at birth because of lung injury resulting from aberrant
hydrolysis of lung surfactant phospholipids, and that the lungs
of newborn Pla2g5-Tg mice are characterized by abnormally
thickened alveolar walls with formation of hyaline membranes
lining the alveolar surfaces [11]. In marked contrast, the alveolar
architecture of Pla2g3-Tg mice was largely indistinguishable
from that of age-matched WT mice (Figure 4A, panels a and
b). When surfactant lipids were extracted from bronchoalveolar
lavage ﬂuid of WT and Pla2g3-Tg mice and were subjected
to ESI–MS analysis, the composition of the surfactant PC
(Figure 4B) and phosphatidylglycerol (results not shown) was
similar in WT and Pla2g3-Tg mice. However, goblet cell
hyperplasia, which was visualized by PAS staining, was evident
in the bronchial epithelium of Pla2g3-Tg mice compared with
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Figure 2 Increases in expression of cytokines/chemokines and inﬁltration of neutrophils/macrophages in skin of Pla2g3-Tg mice
(A) RNAs prepared from the skin of WT mice (left-hand lanes) and Pla2g3-Tg mice (III-Tg; right-hand lanes) were subjected to RT–PCR to assess the expression of pro-inﬂammatory (TNFα,I L - 1 β
and IL-6), TH2 (IL-4) and TH1 (IFNγ and IL-12 p40 subunit) cytokines, and chemokines (CCL2 and CXCL14). RT–PCR for GAPDH was also carried out to verify equal loading of samples into each
lane. (B) MPO activity in homogenates of WT and Pla2g3-Tg (III-Tg) skin (means+ −S.D., n=3). (C) Expression of CD68, a macrophage marker, in skin from WT mice and Pla2g3-Tg mice (III-Tg)
was assessed using quantitative RT–PCR (means+ −S.D., n=3). (D) Expression of mMCP-4, -5 and -6 (mast cell proteases) and HDC in WT and Tg skin.
WT mice, suggesting increased mucus secretion in the former
(Figure 4A, panels c and d). In addition, perivascular lymph
aggregates were frequently found in the lungs of Pla2g3-Tg mice
compared with WT mice (Figure 4A, panels e and f). These
observations suggest that PLA2G3 elicits airway inﬂammation
through a mechanism independent of increased lung surfactant
hydrolysis.
We also found notable inﬂammatory changes in salivary glands
(Figure 4C) and liver (Figure 4D) of Pla2g3-Tg mice. Compared
with WT mice (Figure 4C, panel a), the salivary glands of
Pla2g3-Tgmiceshowedmarkedglandularswellingaccompanied
by inﬁltration of lymphocytes in the interstitium (Figure 4C,
panels b and c); this histological feature resembles lymphocytic
sialadenitis in humans. In addition, foci of extramedullary
haemopoiesis, an event that often occurs during systemic inﬂam-
mation, were found in the liver of Pla2g3-Tg mice (Figure 4D,
panel b), whereas they were absent from WT mice
(Figure 4D, panel a).
Furthermore, Pla2g3-Tg mice, even at 5 months of age at
whichtimenoskininﬂammationwasapparent,frequentlyshowed
splenomegaly (Figure 5A), such that spleen weight in the Tg
mice was markedly increased compared with that in WT mice
(Figure 5B). We therefore examined splenic cell populations
by FACS analysis using antibodies against cell lineage-speciﬁc
markers. Figure 5(C) summarizes the results. Essentially, there
were no appreciable differences in populations of effector T-cells,
including CD4
+ and CD8
+ T-cells, various differential stages
of B-cells, including CD21
+,s I g M
+,s I g D
+ and CD23
+ cells,
and NK (natural killer) (NK1.1
+) cells (Figure 5C). In contrast,
splenic Gr-1
+ neutrophils, CD11b
+ monocytes/macrophages and
CD11c
+ dendritic cells were increased >2-fold in Pla2g3-Tg
mice relative to WT mice (Figure 5C). Therefore PLA2G3
overexpressionpreferentiallyaffectsthehaemopoietic,ratherthan
the lymphocytic, lineages of splenic cells at this stage.
In agreement with the above observations, numbers of
circulating granulocytes and monocytes were increased in 9–10-
month-old Pla2g3-Tg mice compared with WT mice, whereas
they were similar in young adults (2–3-months-old) of both
genotypes (Figure 6A, panels a and b). The number of circulating
lymphocytes tended to increase in young, rather than aged,
PLA2G3 mice relative to WT mice, although this difference
was not statistically signiﬁcant (Figure 6A, panel c). Platelet and
erythrocytecountswereunaffectedinPla2g3-Tgmicethroughout
the experimental periods (Figure 6A, panels d and e). Likewise,
haemoglobin levels and haematocrit values in the blood were
indistinguishable betweenthegenotypes(Figure6B).Inaddition,
serum IgG1 was increased >7-fold in aged Pla2g3-Tg mice
relative to WT mice, whereas serum IgM, IgG2a and IgE levels
were unchanged (Figure 6C).
ToexaminefurtherthepotentialcontributionofPLA2G3tothe
inﬂammatory response, we examined PGE2 generation ex vivo by
peritoneal macrophages derived from Pla2g3-Tg and WT mice.
Spontaneous production of PGE2 over 12 h of culture was higher
in macrophages from Tg mice than in those from control mice
(Figure 6D, panel a). After stimulation of macrophages with LPS
(lipopolysaccharide) for 24 h, WT-derived cells showed vigorous
production of PGE2, which was further augmented 3-fold in
replicate Tg-derived cells (Figure 6D, panel b). These ex vivo
experiments agree with our previous observations that PLA2G3
has the capacity to augment arachidonic acid metabolism in
various cultured cells when overexpressed [14,15]. Moreover,
LPS-stimulated Pla2g3-Tg macrophages produced more IL-6
than did replicate WT cells (Figure 6E). Even in the absence
of LPS stimulation, IL-6 release was signiﬁcantly increased
in macrophages of Pla2g3-Tg mice compared with those of
control mice (Figure 6E, inset). Thus overexpression of PLA2G3
enhances the inﬂammatory response in macrophages.
DISCUSSION
Because of the ability of PLA2 enzymes to release arachidonic
acid(aprecursorofvariouslipidmediatorssuchasprostaglandins
andleukotrienes)andlysophospholipidssuchaslysophosphatidic
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Figure 3 Elevations of PGE2 and its biosynthetic enzymes in skin of Pla2g3-Tg mice
(A) Skin homogenates from WT mice and Pla2g3-Tg mice (III-Tg) were subjected to PGE2 enzyme immune assay. (B) Expression of PGE2-biosynthetic enzymes in skins of WT and Pla2g3-Tg
(III-Tg) mice was assessed by quantitative RT–PCR (means+ −S.D., n=3). The PGE2-biosynthetic pathway is indicated. PGH2, prostaglandin H2.( C) Expression of sPLA2si nW Ta n d
Pla2g3-Tg (Tg) skin was assessed by RT–PCR.
acid and 1-O-alkyl lysophosphatidylcholine [a precursor of PAF
(platelet-activating factor)] from membrane phospholipids, it has
longbeenthoughtthattheseenzymesparticipateinawidevariety
of diseases, such as inﬂammation, atherosclerosis and cancer,
in which lipid mediators play pivotal roles. Gene ablation of
group IVA cPLA2α, a stimulus-coupled intracellular PLA2 that
is regulated by phosphorylation and Ca
2+-dependent membrane
translocation,hasestablishedtheimportanceofthisarachidonate-
selective enzyme in the production of eicosanoids and PAF in
most, if not all, cells and tissues [19]. Although several sPLA2s
arecapableofreleasingarachidonicacidfromisolatedorcultured
cells in vitro [1–3], the pathophysiological relevance of this event
in vivo has remained elusive. Although PLA2G2A is a prototypic
inﬂammatoryPLA2 whoseexpressionismarkedlyelevatedduring
various inﬂammatory states in humans and experimental animals
(except in mice, in which the Pla2g2a gene is naturally disrupted
(e.g. C57BL/6) or expressed only in the intestine (e.g. BALB/c
[20]), its contribution to lipid mediator production in vivo has not
yet been proven conclusively. Tg mice overexpressing human
or mouse PLA2G2A do not show any sign of inﬂammation,
although they display a notable alopecic phenotype with
hyperkeratosis [4,21]. Furthermore, animals overexpressing the
mouseenzymearesensitivetotwo-stagechemicalcarcinogenesis,
with development of a higher number of skin papillomas and then
ofcarcinomasthaninreplicatecontrolmice[21].Rather,themain
function of PLA2G2A is now recognized to be protection of the
host from microbial invasion by degrading bacterial membranes,
in which phosphatidylethanolamine and phosphatidylglycerol,
two preferred substrates for PLA2G2A, are major phospholipid
components [9]. PLA2G5 and PLA2G10 have much higher
capacity to interact with PC-rich outer plasma membranes to
release arachidonic acid than does PLA2G2A [22,23]. The
involvement of both PLA2G5 and PLA2G10 in inﬂammation and
associated lipid-mediator production, such as zymosan-induced
peritonitis [5], methacholine-induced airway hypersensitivity [6],
TH2-biased asthmatic response [7] and ischaemia/reperfusion-
inducedmyocardialdamage[8],hasbeendemonstratedinstudies
using Pla2g5-null or Pla2g10-null mice, even though it remains
uncertain whether arachidonic acid is supplied directly through
the membrane-hydrolytic action of these sPLA2s or indirectly
through the activation of cPLA2α or other enzymes in those
situations.
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Figure 4 Inﬂammatory symptoms in multiple tissues of Pla2g3-Tg mice
(A) Histology of lungs from 1-year-old WT (panels a, c and e) and Pla2g3-Tg (III-Tg) mice (panels b, d and f). No overt abnormalities were found in the alveoli of Pla2g3-Tg mice (III-Tg; panel b)
comparedwithWTmice(panelc).PASstainingrevealedincreasedgobletcells(greenarrows)inthebronchialepitheliumofPla2g3-Tgmice(paneld)comparedwithWTmice(panelc).Perivascular
lymph aggregates (blue arrows) were frequently found in the lung of Pla2g3-Tg mice (panel f) relative to WT mice (panel e). (B) ESI–MS analyses of lung surfactant (PC) prepared from WT mice
(upper panel) and Pla2g3-Tg mice (III-Tg) (lower panel). Peaks for major PC molecular species and an internal standard (PC with C14:1–C14:1) are indicated. No abnormality was found in the lung
surfactant of Pla2g3-Tg mice. I.S., internal standard. (C) Histology of salivary glands of 1-year-old WT mice (panel a) and Pla2g3-Tg mice (III-Tg; panels b and c). Salivary glands of Pla2g3-Tg
mice showed glandular swelling (dark arrows) and interstitial lymphocyte inﬁltration (asterisks). Magniﬁcations, ×200 in panels a and b; ×400 in panel c. (D) Histology of livers from 1-year-old
WT mice (panel a) and Pla2g3-Tg mice (III-Tg; panel b). Extramedullary haemopoiesis was found in the Pla2g3-Tg mice (red arrow; panel b). Magniﬁcation, ×200.
In the present study, we found that Tg mice carrying the
transgene for human PLA2G3, another sPLA2 that is capable
of efﬁcient hydrolysis of PC-rich membranes [14,15], frequently
developed inﬂammation as they aged. This is, to our knowledge,
the ﬁrst demonstration that Tg overexpression of a particular
form of sPLA2 induces inﬂammation in the skin. By 1
year of age, Pla2g3-Tg mice displayed dermatitis associated
with acanthosis, hyperkeratosis, parakeratosis, sebaceous gland
hyperplasia, erosion and ulcer, with massive dermal inﬁltration
of inﬂammatory cells, such as neutrophils and macrophages,
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Figure 5 Altered splenic cell populations in Pla2g3-Tg mice
(A) Splenomegaly of 5-month-old Pla2g3-Tg mice (III-Tg) in comparison with that of age-matched WT mice. (B) Spleen weight per body weight was nearly doubled in Pla2g3-Tg mice (III-Tg)
relative to that in WT mice (means+ −S.D., n=4, *P <0.05). (C) Distribution of splenic cell populations in WT and Pla2g3-Tg (III-Tg) mice. FACS was performed with antibodies for CD3 (T-cells),
CD45R (B-cells), NK1.1 (NK cells), Gr-1 (granulocytes), CD11c (dendritic cells) and CD11b (monocytes/macrophages) (left-hand panel). T-cell lineages were sorted further with antibodies for CD4
and CD8, and B-cell lineages were sorted with antibodies for CD21, CD23, sIgM and sIgD (right-hand panel). Values are means+ −S.D. for three independent experiments (*P <0.05).
and elevated expression of pro-inﬂammatory cytokines and
chemokines, such as IL-1β, IL-6, TNFα and CCL2 (Figures 1
and 2). A moderate but signiﬁcant expression of IL-4, but
not IFNγ and IL-12, suggests a tendency to a TH2 response
rather than a TH1 response. The affected skin in Pla2g3-Tg
mice is histologically similar to that of patients with atopic
dermatitis, but is distinct from that of Pla2g2a-Tg mice [4],
which develop alopecia and epidermal hyperplasia in the absence
of inﬂammation. Therefore the mechanisms underlying the
skin phenotypes induced by PLA2G3 (with inﬂammation) and
PLA2G2A (without inﬂammation) may not be identical.
PGE2, as well as its biosynthetic enzymes (COX-2 and
mPGES-1), was markedly increased in skin lesions of Pla2g3-Tg
mice (Figure 3), indicating that PLA2G3 facilitates arachidonic
acid metabolism. At present, it is unclear whether the elevation
of this arachidonate metabolite reﬂects increased PLA2G3-
directed membrane hydrolysis or a secondary effect involving
the activation of other PLA2s (such as cPLA2α) in inﬁltrating
leucocytes,keratinocytesorothercelltypesinresponsetoelevated
levels of pro-inﬂammatory cytokines/chemokines. Nevertheless,
peritoneal macrophages from Pla2g3-Tg mice produced more
PGE2 and IL-6 than did those from control mice, particularly
after stimulation with LPS (Figures 6D and 6E), an observation
that accords with studies showing that PLA2G3 can promote
arachidonic acid release in multiple types of cultured cells
[14,15] and that the skin lesions in Pla2g3-Tg mice showed
elevated levels of pro-inﬂammatory cytokines and PGE2 with
a concomitant inﬁltration of macrophages (Figures 2 and 3).
The inﬂammatory signs are not restricted to the skin, but
are also seen in other tissues including salivary gland, lung,
liver, spleen and even blood (Figures 4–6). In this context,
a likely explanation for the inﬂammatory phenotype is that
sustained, albeit moderate, increases in levels of lipid mediators
within the affected tissues might lead to a gradual onset of
inﬂammation in Pla2g3-Tg mice. For instance, PGE2, through
its receptor EP2, promotes epidermal hyperplasia and dermal
macrophage inﬁltration [23a], which are reminiscent of Pla2g3-
Tg skin (Figure 1). In accordance, episodes of infection
with environmental micro-organisms through cutaneous lesions,
particularly wounded areas as a result of increasing scratching
behaviour,mightfacilitatetheexpansion,migrationandactivation
of neutrophils and macrophages, thereby leading to exacerba-
tion of local and systemic inﬂammatory responses.
It is intriguing to note that the skin inﬂammation in Pla2g3-Tg
mice was accompanied by increased expression of PLA2G5 and
PLA2G2D (Figure 3C). This suggests that these two sPLA2sa r e
associated with inﬂammation, either through transcriptional up-
regulation in resident cells or through inﬁltration of inﬂammatory
cells in which these sPLA2s are expressed. Both situations might
beappliedtoPLA2G5,sincethisenzymeisknowntobeexpressed
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Group III sPLA2 transgenic mice and inﬂammation 25
Figure 6 Changes in circulating cell populations and serum immunoglobulin levels in Pla2g3-Tg mice
The numbers of circulating granulocytes, monocytes, lymphocytes, platelets and erythrocytes (A), as well as haemoglobin and haematocrit values (B), in young (11–13-week-old) and aged
(38–41-week-old) WT and Pla2g3-Tg (Tg) mice were evaluated using VetScan HM (means+ −S.D., n=4–12, *P <0.05). (C) Serum concentrations of IgG1, IgM, IgG2a and IgM were determined
by sandwich ELISA (means+ −S.D., n=3, *P <0.05). (D) Peritoneal macrophages from Pla2g3-Tg (III-Tg) and WT mice were cultured for the indicated periods in culture medium (left-hand panel)
orfor24hinmediumwith(+)orwithout(−)1μg/mlLPS(right-handpanel).ThesupernatantsweretakenforPGE2 enzymeimmuneassay.Arepresentativeresultoftworeproducibleresults(panel
a) and means+ −S.E.M. for four experiments (panel b) are shown. *P <0.05 compared with replicate WT cells. (E) Peritoneal macrophages from Pla2g3-Tg (III-Tg) and WT mice were cultured for
24 h in culture medium with (+) or without (−) LPS (right-hand panel). The supernatants were taken for ELISA for IL-6 (means+ −S.E.M., n=4, *P <0.05 compared with replicate WT cells). Inset,
IL-6 production by the cells cultured in the absence of LPS is magniﬁed.
in macrophages [24], a cell population which is increased in
Pla2g3-Tg skin, and since its expression has been reported to
be induced in cytokine-stimulated macrophage-like cells [25] and
keratinocytes [26]. Increased expression of PLA2G2D has been
reported in a mouse model of atopic dermatitis [27]. On the other
hand, PLA2G2E and PLA2G2F, as well as endogenous PLA2G3,
wereconsistentlydetectedinWTandPla2g3-Tgskin(Figure3C),
suggestingthatthesesPLA2 enzymesareconstitutivelyexpressed
in certain resident cells, rather than in inﬁltrating leucocytes,
within the skin niche. Importantly, judging from the intensity of
RT–PCR bands, the expression of endogenousmouse PLA2G3 in
WT skin is similar to that of human PLA2G3 overexpressed
in Tg skin (Figure 3C), suggesting a potential contribution of
this enzyme to skin inﬂammation under certain pathological
conditions. In contrast with previous reports describing the
expression of PLA2G10 in newborn mouse skin [28], we failed
to detect its transcript in the skin of either WT or Pla2g3-Tg mice
(Figure 3C); this might be due to the difference in ages or strains
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examined (neonatal NMRI mice compared with aged C57BL/6
mice).
Aswehavereportedrecently,alterationsinplasmalipoproteins
[a decrease in HDL (high-density lipoprotein) and an increase
in atherogenic LDL (low-density lipoprotein)] occur in Pla2g3-
Tg mice [16]. Interestingly, a potential linkage between
altered lipoprotein levels and chronic inﬂammatory diseases has
been proposed [29–32]. Mice deﬁcient in LDL receptor and
apolipoprotein A-I, in which plasma cholesterol levels were
markedly altered, suffered from increasingly severe ulcerated
cutaneous inﬂammation, and, in these mice, cholesterol accumu-
lation in the skin was associated with macrophage inﬁltration
and was accompanied by increases in TNFα and COX-2
[29,30]. Tg overexpression of apolipoprotein C1 decreased
lipids in the sebaceous gland, epidermis and subcutaneous
adipose tissue, leading to dry and scaly skin with loss of hair,
epidermal hyperplasia, hyperkeratosis and atrophic sebaceous
glands lacking sebum [31]. An increase in circulating HDL led
to a signiﬁcant inhibition of basal and IL-1α-induced E-selectin
expression, suggesting the potential anti-inﬂammatory action of
HDL [32]. These observations raise the possibility that systemic
alterations in circulating LDL and HDL in Pla2g3-Tg mice [16]
might be responsible, at least in part, for the acceleration of
inﬂammation. Interestingly, Pla2g2a-Tg mice, which develop
skin abnormalities [4], also show reduced plasma HDL levels
[10], and disturbance of systemic lipid homoeostasis has often
been linked with skin abnormalities in various mouse models
and even in human diseases [33–35]. Therefore potential causal
relationships between altered systemic lipoprotein levels and
skin abnormalities in mouse models with Tg overexpression of
particularformsofsPLA2 shouldbetakenintoaccount.Moreover,
given the recent recognition that atherosclerosis is a form of
chronicinﬂammationinthevascularwall[36],theatherosclerotic
[16] and inﬂammatory (the present study) phenotypes of Pla2g3-
Tg mice may be interrelated.
Endogenous PLA2G3 mRNA in humans is detected in several
tissues such as kidney, heart, liver and skeletal muscle [13], and
immunoreactive PLA2G3 protein is localized in microvascular
endothelial cells, macrophages, peripheral neuronal ﬁbres,
atherosclerotic plaques and tumour cells in tissues from
human subjects with diseases (e.g. inﬂammation, ischaemia,
atherosclerosis and cancer) [15,16,37,38]. In mice, endogenous
Pla2g3 mRNA is detected at trace levels in various tissues (H.
Sato, Y. Taketomi and M. Murakami, unpublished work), among
which the nervous system (e.g. brain, spinal cord and dorsal root
ganglion) shows the highest expression [37]. Essentially, unlike
PLA2G2A, whose tissue expression proﬁles differ considerably
between human and mouse [20], it appears that human and
mouse PLA2G3 orthologues (∼82% homology in their core
S domain) display a similar, if not entirely identical, tissue
distribution pattern. In cell culture systems, forcible expression
or exogenous addition of human PLA2G3 facilitates the axonal
growth and survival of neuronal cells, proliferation of colorectal
cancercells,maturationofdendriticcells,migrationofendothelial
cells and inhibition of viral infection, whereas introduction of
PLA2G3-directed small interfering RNA partially suppresses
some of these events, probably through altering the cellular
levels of lysophospholipids or eicosanoids [14,15,37,39,40].
Detection of endogenous PLA2G3 in mouse skin (Figure 3C)
raises the intriguing possibility that this unique type of sPLA2
might function in skin biology. Besides the effect of PLA2G3
on lipid mediator generation, PLA2G3 might be coupled with
a particular signalling pathway through interacting with the
putative N-type sPLA2 receptor, to which bee venom PLA2 (a
PLA2G3 homologue) is known to bind as a ligand [41]. It will be
necessary to reconcile the precise in vivo actions, expression and
dynamics of PLA2G3 by conducting studies with Pla2g3 gene-
disruptedmiceorwithPLA2G3-speciﬁcinhibitors.Nevertheless,
despite the limitations of Tg overexpression strategies, the
mouse model described in the present paper might be useful
to uncover the molecular actions of sPLA2 family enzymes,
including tissue-speciﬁc target substrates and their metabolites,
during the process of inﬂammation or other related diseases.
Furthermore, this mouse line has potential for the screening
of novel anti-inﬂammatory agents aiming at inhibiting sPLA2-
mediated phospholipid hydrolysis.
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